SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (NASDAQ: AFFX) today announced the availability of its Drug Metabolizing Enzymes and Transporters (DMET) Early Access solution, currently the world’s most comprehensive method for assaying the genetics of drug metabolism. The DMET offering profiles more than 1,069 drug metabolism biomarkers, including 172 “core” genetic markers. Data is automatically interpreted into a common format that can be integrated into clinical trial workflows. The information enables researchers to make more informed drug-development decisions, which in turn significantly streamlines the drug-development process and, therefore, time to market.
